nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—FKBP1A—Cyclosporine—psoriasis	0.221	0.32	CbGbCtD
Temsirolimus—CYP3A5—Beclomethasone—psoriasis	0.0532	0.0771	CbGbCtD
Temsirolimus—CYP2D6—Hydroxyurea—psoriasis	0.0247	0.0358	CbGbCtD
Temsirolimus—CYP3A7—Hydrocortisone—psoriasis	0.0227	0.0328	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0227	0.0328	CbGbCtD
Temsirolimus—CYP3A7—Cyclosporine—psoriasis	0.0214	0.031	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0214	0.031	CbGbCtD
Temsirolimus—CYP3A5—Mycophenolate mofetil—psoriasis	0.0212	0.0307	CbGbCtD
Temsirolimus—CYP3A4—Calcitriol—psoriasis	0.0185	0.0268	CbGbCtD
Temsirolimus—CYP3A5—Hydrocortisone—psoriasis	0.017	0.0246	CbGbCtD
Temsirolimus—CYP3A5—Cyclosporine—psoriasis	0.0161	0.0233	CbGbCtD
Temsirolimus—CYP2D6—Cholecalciferol—psoriasis	0.015	0.0217	CbGbCtD
Temsirolimus—CYP3A4—Methoxsalen—psoriasis	0.0144	0.0208	CbGbCtD
Temsirolimus—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.0141	0.0204	CbGbCtD
Temsirolimus—CYP3A7—Dexamethasone—psoriasis	0.0141	0.0204	CbGbCtD
Temsirolimus—ABCB1—Mycophenolate mofetil—psoriasis	0.0138	0.02	CbGbCtD
Temsirolimus—ABCB1—Betamethasone—psoriasis	0.0118	0.0171	CbGbCtD
Temsirolimus—ABCB1—Prednisolone—psoriasis	0.0117	0.0169	CbGbCtD
Temsirolimus—ABCB1—Hydrocortisone—psoriasis	0.0111	0.016	CbGbCtD
Temsirolimus—ABCB1—Prednisone—psoriasis	0.011	0.016	CbGbCtD
Temsirolimus—CYP3A5—Dexamethasone—psoriasis	0.0106	0.0153	CbGbCtD
Temsirolimus—ABCB1—Cyclosporine—psoriasis	0.0104	0.0151	CbGbCtD
Temsirolimus—CYP2D6—Cyclosporine—psoriasis	0.00984	0.0143	CbGbCtD
Temsirolimus—CYP3A4—Cholecalciferol—psoriasis	0.00953	0.0138	CbGbCtD
Temsirolimus—CYP3A4—Mycophenolate mofetil—psoriasis	0.00826	0.012	CbGbCtD
Temsirolimus—CYP3A4—Triamcinolone—psoriasis	0.00826	0.012	CbGbCtD
Temsirolimus—CYP3A4—Betamethasone—psoriasis	0.00709	0.0103	CbGbCtD
Temsirolimus—CYP3A4—Prednisolone—psoriasis	0.00699	0.0101	CbGbCtD
Temsirolimus—ABCB1—Dexamethasone—psoriasis	0.00688	0.00997	CbGbCtD
Temsirolimus—CYP3A4—Hydrocortisone—psoriasis	0.00663	0.0096	CbGbCtD
Temsirolimus—CYP3A4—Prednisone—psoriasis	0.0066	0.00957	CbGbCtD
Temsirolimus—CYP2D6—Dexamethasone—psoriasis	0.00648	0.00939	CbGbCtD
Temsirolimus—CYP3A4—Cyclosporine—psoriasis	0.00626	0.00907	CbGbCtD
Temsirolimus—ABCB1—Methotrexate—psoriasis	0.00553	0.00801	CbGbCtD
Temsirolimus—CYP3A4—Dexamethasone—psoriasis	0.00412	0.00597	CbGbCtD
Temsirolimus—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000123	0.00208	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—TYK2—psoriasis	0.000122	0.00207	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—TNF—psoriasis	0.000122	0.00206	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000118	0.002	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—NFKBIA—psoriasis	0.000118	0.00199	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—psoriasis	0.000116	0.00197	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—NFKB1—psoriasis	0.000115	0.00196	CbGpPWpGaD
Temsirolimus—MTOR—TSLP Signaling Pathway—IL6—psoriasis	0.000115	0.00195	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—TYK2—psoriasis	0.000115	0.00195	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—TYK2—psoriasis	0.000114	0.00194	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TAGAP—psoriasis	0.000114	0.00194	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—STAT3—psoriasis	0.000114	0.00192	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—TP53—psoriasis	0.000113	0.00191	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000111	0.00187	CbGpPWpGaD
Temsirolimus—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	0.00011	0.00186	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—CXCL8—psoriasis	0.000108	0.00183	CbGpPWpGaD
Temsirolimus—CYP3A4—Tryptophan metabolism—CAT—psoriasis	0.000107	0.00182	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—TP53—psoriasis	0.000107	0.00182	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—IL10—psoriasis	0.000107	0.00181	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000106	0.0018	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKBIA—psoriasis	0.000104	0.00177	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—IL4—psoriasis	0.000104	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—STAT3—psoriasis	0.000104	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—psoriasis	0.000104	0.00176	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—HLA-B—psoriasis	0.000101	0.00172	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000101	0.00172	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—JUN—psoriasis	0.0001	0.0017	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—JUN—psoriasis	0.0001	0.0017	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—CAT—psoriasis	0.0001	0.00169	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKBIA—psoriasis	9.97e-05	0.00169	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—IL6—psoriasis	9.82e-05	0.00166	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—TYK2—psoriasis	9.79e-05	0.00166	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—psoriasis	9.72e-05	0.00165	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	9.66e-05	0.00164	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	9.45e-05	0.0016	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—HLA-A—psoriasis	9.4e-05	0.00159	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—TYK2—psoriasis	9.37e-05	0.00159	CbGpPWpGaD
Temsirolimus—MTOR—AMPK Signaling—TP53—psoriasis	9.27e-05	0.00157	CbGpPWpGaD
Temsirolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.25e-05	0.00157	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—NFKBIA—psoriasis	9.22e-05	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—TYK2—psoriasis	9.22e-05	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—ITGAL—psoriasis	9.06e-05	0.00153	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriasis	8.98e-05	0.00152	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—TYK2—psoriasis	8.81e-05	0.00149	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—TYK2—psoriasis	8.76e-05	0.00148	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—TYK2—psoriasis	8.72e-05	0.00148	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—STAT3—psoriasis	8.68e-05	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—TYK2—psoriasis	8.68e-05	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—psoriasis	8.63e-05	0.00146	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	8.59e-05	0.00145	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—IFIH1—psoriasis	8.57e-05	0.00145	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—REL—psoriasis	8.48e-05	0.00144	CbGpPWpGaD
Temsirolimus—Pruritus—Mycophenolic acid—psoriasis	8.38e-05	0.000334	CcSEcCtD
Temsirolimus—Myalgia—Triamcinolone—psoriasis	8.36e-05	0.000333	CcSEcCtD
Temsirolimus—Nervous system disorder—Hydrocortisone—psoriasis	8.35e-05	0.000333	CcSEcCtD
Temsirolimus—Pneumonia—Methotrexate—psoriasis	8.35e-05	0.000333	CcSEcCtD
Temsirolimus—Eye disorder—Prednisone—psoriasis	8.33e-05	0.000332	CcSEcCtD
Temsirolimus—Dyspnoea—Mycophenolate mofetil—psoriasis	8.33e-05	0.000332	CcSEcCtD
Temsirolimus—Decreased appetite—Cyclosporine—psoriasis	8.33e-05	0.000332	CcSEcCtD
Temsirolimus—Somnolence—Mycophenolate mofetil—psoriasis	8.31e-05	0.000331	CcSEcCtD
Temsirolimus—Infestation—Methotrexate—psoriasis	8.3e-05	0.000331	CcSEcCtD
Temsirolimus—Infestation NOS—Methotrexate—psoriasis	8.3e-05	0.000331	CcSEcCtD
Temsirolimus—Depression—Methotrexate—psoriasis	8.28e-05	0.00033	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	8.28e-05	0.0014	CbGpPWpGaD
Temsirolimus—Gastrointestinal disorder—Cyclosporine—psoriasis	8.27e-05	0.00033	CcSEcCtD
Temsirolimus—Skin disorder—Hydrocortisone—psoriasis	8.27e-05	0.00033	CcSEcCtD
Temsirolimus—Fatigue—Cyclosporine—psoriasis	8.26e-05	0.000329	CcSEcCtD
Temsirolimus—MTOR—Immune System—ERAP1—psoriasis	8.24e-05	0.0014	CbGpPWpGaD
Temsirolimus—Stevens-Johnson syndrome—Methotrexate—psoriasis	8.23e-05	0.000328	CcSEcCtD
Temsirolimus—Constipation—Cyclosporine—psoriasis	8.19e-05	0.000327	CcSEcCtD
Temsirolimus—Pain—Cyclosporine—psoriasis	8.19e-05	0.000327	CcSEcCtD
Temsirolimus—MTOR—DAP12 interactions—TYK2—psoriasis	8.16e-05	0.00138	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TYK2—psoriasis	8.16e-05	0.00138	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—TYK2—psoriasis	8.16e-05	0.00138	CbGpPWpGaD
Temsirolimus—Renal failure—Methotrexate—psoriasis	8.16e-05	0.000325	CcSEcCtD
Temsirolimus—MTOR—Signaling by VEGF—VEGFA—psoriasis	8.15e-05	0.00138	CbGpPWpGaD
Temsirolimus—Angioedema—Betamethasone—psoriasis	8.15e-05	0.000325	CcSEcCtD
Temsirolimus—Angioedema—Dexamethasone—psoriasis	8.15e-05	0.000325	CcSEcCtD
Temsirolimus—Decreased appetite—Mycophenolate mofetil—psoriasis	8.13e-05	0.000324	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—HLA-C—psoriasis	8.12e-05	0.00138	CbGpPWpGaD
Temsirolimus—Anorexia—Hydrocortisone—psoriasis	8.12e-05	0.000324	CcSEcCtD
Temsirolimus—Diarrhoea—Mycophenolic acid—psoriasis	8.1e-05	0.000323	CcSEcCtD
Temsirolimus—Stomatitis—Methotrexate—psoriasis	8.09e-05	0.000323	CcSEcCtD
Temsirolimus—Angiopathy—Prednisone—psoriasis	8.09e-05	0.000323	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—TYK2—psoriasis	8.09e-05	0.00137	CbGpPWpGaD
Temsirolimus—Conjunctivitis—Methotrexate—psoriasis	8.07e-05	0.000322	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	8.07e-05	0.000322	CcSEcCtD
Temsirolimus—Immune system disorder—Prednisone—psoriasis	8.06e-05	0.000321	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—TNFAIP3—psoriasis	8.02e-05	0.00136	CbGpPWpGaD
Temsirolimus—Oedema—Triamcinolone—psoriasis	8.02e-05	0.00032	CcSEcCtD
Temsirolimus—Anaphylactic shock—Triamcinolone—psoriasis	8.02e-05	0.00032	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—TYK2—psoriasis	8.02e-05	0.00136	CbGpPWpGaD
Temsirolimus—Constipation—Mycophenolate mofetil—psoriasis	7.99e-05	0.000319	CcSEcCtD
Temsirolimus—Pain—Mycophenolate mofetil—psoriasis	7.99e-05	0.000319	CcSEcCtD
Temsirolimus—MTOR—Signaling by PDGF—TYK2—psoriasis	7.98e-05	0.00135	CbGpPWpGaD
Temsirolimus—Infection—Triamcinolone—psoriasis	7.97e-05	0.000318	CcSEcCtD
Temsirolimus—Haematuria—Methotrexate—psoriasis	7.92e-05	0.000316	CcSEcCtD
Temsirolimus—Insomnia—Prednisolone—psoriasis	7.89e-05	0.000314	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Cyclosporine—psoriasis	7.84e-05	0.000312	CcSEcCtD
Temsirolimus—Dizziness—Mycophenolic acid—psoriasis	7.83e-05	0.000312	CcSEcCtD
Temsirolimus—Epistaxis—Methotrexate—psoriasis	7.83e-05	0.000312	CcSEcCtD
Temsirolimus—Mental disorder—Prednisone—psoriasis	7.81e-05	0.000311	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—HLA-C—psoriasis	7.8e-05	0.00132	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—JUN—psoriasis	7.79e-05	0.00132	CbGpPWpGaD
Temsirolimus—Malnutrition—Prednisone—psoriasis	7.76e-05	0.000309	CcSEcCtD
Temsirolimus—Erythema—Prednisone—psoriasis	7.76e-05	0.000309	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Hydrocortisone—psoriasis	7.76e-05	0.000309	CcSEcCtD
Temsirolimus—Convulsion—Betamethasone—psoriasis	7.72e-05	0.000308	CcSEcCtD
Temsirolimus—Convulsion—Dexamethasone—psoriasis	7.72e-05	0.000308	CcSEcCtD
Temsirolimus—Insomnia—Hydrocortisone—psoriasis	7.7e-05	0.000307	CcSEcCtD
Temsirolimus—Hypertension—Betamethasone—psoriasis	7.7e-05	0.000307	CcSEcCtD
Temsirolimus—Hypertension—Dexamethasone—psoriasis	7.7e-05	0.000307	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	7.64e-05	0.000305	CcSEcCtD
Temsirolimus—Myalgia—Dexamethasone—psoriasis	7.59e-05	0.000303	CcSEcCtD
Temsirolimus—Myalgia—Betamethasone—psoriasis	7.59e-05	0.000303	CcSEcCtD
Temsirolimus—Body temperature increased—Cyclosporine—psoriasis	7.58e-05	0.000302	CcSEcCtD
Temsirolimus—Abdominal pain—Cyclosporine—psoriasis	7.58e-05	0.000302	CcSEcCtD
Temsirolimus—Anxiety—Dexamethasone—psoriasis	7.56e-05	0.000301	CcSEcCtD
Temsirolimus—Anxiety—Betamethasone—psoriasis	7.56e-05	0.000301	CcSEcCtD
Temsirolimus—Vomiting—Mycophenolic acid—psoriasis	7.53e-05	0.0003	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—JUN—psoriasis	7.5e-05	0.00127	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—NFKB1—psoriasis	7.5e-05	0.00127	CbGpPWpGaD
Temsirolimus—Rash—Mycophenolic acid—psoriasis	7.47e-05	0.000298	CcSEcCtD
Temsirolimus—Dermatitis—Mycophenolic acid—psoriasis	7.46e-05	0.000297	CcSEcCtD
Temsirolimus—Pain—Prednisolone—psoriasis	7.46e-05	0.000297	CcSEcCtD
Temsirolimus—CYP3A7—Metabolism—NDUFA5—psoriasis	7.44e-05	0.00126	CbGpPWpGaD
Temsirolimus—Headache—Mycophenolic acid—psoriasis	7.42e-05	0.000296	CcSEcCtD
Temsirolimus—MTOR—Signaling Pathways—HCAR2—psoriasis	7.41e-05	0.00126	CbGpPWpGaD
Temsirolimus—Decreased appetite—Hydrocortisone—psoriasis	7.4e-05	0.000295	CcSEcCtD
Temsirolimus—Pharyngitis—Methotrexate—psoriasis	7.4e-05	0.000295	CcSEcCtD
Temsirolimus—Abdominal pain—Mycophenolate mofetil—psoriasis	7.39e-05	0.000295	CcSEcCtD
Temsirolimus—Body temperature increased—Mycophenolate mofetil—psoriasis	7.39e-05	0.000295	CcSEcCtD
Temsirolimus—Urinary tract disorder—Methotrexate—psoriasis	7.36e-05	0.000293	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Hydrocortisone—psoriasis	7.35e-05	0.000293	CcSEcCtD
Temsirolimus—Fatigue—Hydrocortisone—psoriasis	7.34e-05	0.000293	CcSEcCtD
Temsirolimus—Urethral disorder—Methotrexate—psoriasis	7.31e-05	0.000291	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Triamcinolone—psoriasis	7.31e-05	0.000291	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	7.3e-05	0.00124	CbGpPWpGaD
Temsirolimus—Pain—Hydrocortisone—psoriasis	7.28e-05	0.00029	CcSEcCtD
Temsirolimus—Anaphylactic shock—Dexamethasone—psoriasis	7.28e-05	0.00029	CcSEcCtD
Temsirolimus—Oedema—Betamethasone—psoriasis	7.28e-05	0.00029	CcSEcCtD
Temsirolimus—Anaphylactic shock—Betamethasone—psoriasis	7.28e-05	0.00029	CcSEcCtD
Temsirolimus—Oedema—Dexamethasone—psoriasis	7.28e-05	0.00029	CcSEcCtD
Temsirolimus—Insomnia—Triamcinolone—psoriasis	7.25e-05	0.000289	CcSEcCtD
Temsirolimus—MTOR—Immune System—DDX58—psoriasis	7.25e-05	0.00123	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	7.23e-05	0.00122	CbGpPWpGaD
Temsirolimus—Infection—Betamethasone—psoriasis	7.23e-05	0.000288	CcSEcCtD
Temsirolimus—Infection—Dexamethasone—psoriasis	7.23e-05	0.000288	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—NFKB1—psoriasis	7.22e-05	0.00122	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—IL6—psoriasis	7.18e-05	0.00122	CbGpPWpGaD
Temsirolimus—Anaemia—Prednisone—psoriasis	7.18e-05	0.000286	CcSEcCtD
Temsirolimus—MTOR—Insulin Signaling—JUN—psoriasis	7.16e-05	0.00121	CbGpPWpGaD
Temsirolimus—Dyspnoea—Triamcinolone—psoriasis	7.15e-05	0.000285	CcSEcCtD
Temsirolimus—Nervous system disorder—Betamethasone—psoriasis	7.14e-05	0.000284	CcSEcCtD
Temsirolimus—Nervous system disorder—Dexamethasone—psoriasis	7.14e-05	0.000284	CcSEcCtD
Temsirolimus—Thrombocytopenia—Dexamethasone—psoriasis	7.12e-05	0.000284	CcSEcCtD
Temsirolimus—Thrombocytopenia—Betamethasone—psoriasis	7.12e-05	0.000284	CcSEcCtD
Temsirolimus—Angioedema—Prednisone—psoriasis	7.09e-05	0.000283	CcSEcCtD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—psoriasis	7.09e-05	0.0012	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Cyclosporine—psoriasis	7.06e-05	0.000281	CcSEcCtD
Temsirolimus—Erythema multiforme—Methotrexate—psoriasis	7.05e-05	0.000281	CcSEcCtD
Temsirolimus—Nausea—Mycophenolic acid—psoriasis	7.04e-05	0.00028	CcSEcCtD
Temsirolimus—MTOR—IRS-related events—IL6—psoriasis	6.98e-05	0.00118	CbGpPWpGaD
Temsirolimus—Eye disorder—Methotrexate—psoriasis	6.97e-05	0.000278	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Hydrocortisone—psoriasis	6.96e-05	0.000278	CcSEcCtD
Temsirolimus—Anorexia—Betamethasone—psoriasis	6.94e-05	0.000276	CcSEcCtD
Temsirolimus—Anorexia—Dexamethasone—psoriasis	6.94e-05	0.000276	CcSEcCtD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—IL6—psoriasis	6.92e-05	0.00117	CbGpPWpGaD
Temsirolimus—Cardiac disorder—Methotrexate—psoriasis	6.92e-05	0.000276	CcSEcCtD
Temsirolimus—Fatigue—Triamcinolone—psoriasis	6.91e-05	0.000276	CcSEcCtD
Temsirolimus—Hypersensitivity—Mycophenolate mofetil—psoriasis	6.89e-05	0.000275	CcSEcCtD
Temsirolimus—Asthenia—Cyclosporine—psoriasis	6.88e-05	0.000274	CcSEcCtD
Temsirolimus—Pain—Triamcinolone—psoriasis	6.86e-05	0.000273	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—STAT3—psoriasis	6.86e-05	0.00116	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCL20—psoriasis	6.85e-05	0.00116	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—NFKBIA—psoriasis	6.79e-05	0.00115	CbGpPWpGaD
Temsirolimus—Pruritus—Cyclosporine—psoriasis	6.78e-05	0.00027	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—psoriasis	6.76e-05	0.00027	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—HLA-E—psoriasis	6.74e-05	0.00114	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—STAT3—psoriasis	6.74e-05	0.00114	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—IL6—psoriasis	6.74e-05	0.00114	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—IL6—psoriasis	6.74e-05	0.00114	CbGpPWpGaD
Temsirolimus—Immune system disorder—Methotrexate—psoriasis	6.73e-05	0.000268	CcSEcCtD
Temsirolimus—Abdominal pain—Hydrocortisone—psoriasis	6.73e-05	0.000268	CcSEcCtD
Temsirolimus—Body temperature increased—Hydrocortisone—psoriasis	6.73e-05	0.000268	CcSEcCtD
Temsirolimus—Convulsion—Prednisone—psoriasis	6.73e-05	0.000268	CcSEcCtD
Temsirolimus—Mediastinal disorder—Methotrexate—psoriasis	6.72e-05	0.000268	CcSEcCtD
Temsirolimus—Asthenia—Mycophenolate mofetil—psoriasis	6.71e-05	0.000267	CcSEcCtD
Temsirolimus—Hypertension—Prednisone—psoriasis	6.7e-05	0.000267	CcSEcCtD
Temsirolimus—Chills—Methotrexate—psoriasis	6.69e-05	0.000267	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	6.66e-05	0.00113	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Betamethasone—psoriasis	6.63e-05	0.000264	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Dexamethasone—psoriasis	6.63e-05	0.000264	CcSEcCtD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—psoriasis	6.62e-05	0.00112	CbGpPWpGaD
Temsirolimus—Pruritus—Mycophenolate mofetil—psoriasis	6.61e-05	0.000264	CcSEcCtD
Temsirolimus—Myalgia—Prednisone—psoriasis	6.61e-05	0.000263	CcSEcCtD
Temsirolimus—Arthralgia—Prednisone—psoriasis	6.61e-05	0.000263	CcSEcCtD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	6.61e-05	0.00112	CbGpPWpGaD
Temsirolimus—Anxiety—Prednisone—psoriasis	6.59e-05	0.000263	CcSEcCtD
Temsirolimus—Insomnia—Betamethasone—psoriasis	6.58e-05	0.000262	CcSEcCtD
Temsirolimus—Insomnia—Dexamethasone—psoriasis	6.58e-05	0.000262	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	6.56e-05	0.000262	CcSEcCtD
Temsirolimus—Diarrhoea—Cyclosporine—psoriasis	6.56e-05	0.000261	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—psoriasis	6.55e-05	0.00111	CbGpPWpGaD
Temsirolimus—Mental disorder—Methotrexate—psoriasis	6.53e-05	0.00026	CcSEcCtD
Temsirolimus—Malnutrition—Methotrexate—psoriasis	6.49e-05	0.000259	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—psoriasis	6.49e-05	0.000259	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—HLA-E—psoriasis	6.47e-05	0.0011	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TAGAP—psoriasis	6.43e-05	0.00109	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Prednisolone—psoriasis	6.42e-05	0.000256	CcSEcCtD
Temsirolimus—Diarrhoea—Mycophenolate mofetil—psoriasis	6.4e-05	0.000255	CcSEcCtD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	6.36e-05	0.00108	CbGpPWpGaD
Temsirolimus—Dysgeusia—Methotrexate—psoriasis	6.35e-05	0.000253	CcSEcCtD
Temsirolimus—Body temperature increased—Triamcinolone—psoriasis	6.34e-05	0.000253	CcSEcCtD
Temsirolimus—Dizziness—Cyclosporine—psoriasis	6.34e-05	0.000253	CcSEcCtD
Temsirolimus—Anaphylactic shock—Prednisone—psoriasis	6.34e-05	0.000253	CcSEcCtD
Temsirolimus—Oedema—Prednisone—psoriasis	6.34e-05	0.000253	CcSEcCtD
Temsirolimus—CYP3A7—Metabolism—CYP2S1—psoriasis	6.33e-05	0.00107	CbGpPWpGaD
Temsirolimus—Decreased appetite—Dexamethasone—psoriasis	6.32e-05	0.000252	CcSEcCtD
Temsirolimus—Decreased appetite—Betamethasone—psoriasis	6.32e-05	0.000252	CcSEcCtD
Temsirolimus—Infection—Prednisone—psoriasis	6.29e-05	0.000251	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Dexamethasone—psoriasis	6.28e-05	0.00025	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Betamethasone—psoriasis	6.28e-05	0.00025	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—psoriasis	6.28e-05	0.00025	CcSEcCtD
Temsirolimus—Hypersensitivity—Hydrocortisone—psoriasis	6.27e-05	0.00025	CcSEcCtD
Temsirolimus—ABCB1—Allograft Rejection—IFNG—psoriasis	6.27e-05	0.00106	CbGpPWpGaD
Temsirolimus—Fatigue—Betamethasone—psoriasis	6.27e-05	0.00025	CcSEcCtD
Temsirolimus—Fatigue—Dexamethasone—psoriasis	6.27e-05	0.00025	CcSEcCtD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	6.26e-05	0.00106	CbGpPWpGaD
Temsirolimus—Pain—Dexamethasone—psoriasis	6.22e-05	0.000248	CcSEcCtD
Temsirolimus—Pain—Betamethasone—psoriasis	6.22e-05	0.000248	CcSEcCtD
Temsirolimus—Nervous system disorder—Prednisone—psoriasis	6.21e-05	0.000248	CcSEcCtD
Temsirolimus—Dizziness—Mycophenolate mofetil—psoriasis	6.18e-05	0.000246	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—STAT3—psoriasis	6.17e-05	0.00104	CbGpPWpGaD
Temsirolimus—Skin disorder—Prednisone—psoriasis	6.15e-05	0.000245	CcSEcCtD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—psoriasis	6.14e-05	0.00104	CbGpPWpGaD
Temsirolimus—Asthenia—Hydrocortisone—psoriasis	6.11e-05	0.000244	CcSEcCtD
Temsirolimus—Vomiting—Cyclosporine—psoriasis	6.09e-05	0.000243	CcSEcCtD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—IL6—psoriasis	6.06e-05	0.00103	CbGpPWpGaD
Temsirolimus—Rash—Cyclosporine—psoriasis	6.04e-05	0.000241	CcSEcCtD
Temsirolimus—Anorexia—Prednisone—psoriasis	6.04e-05	0.000241	CcSEcCtD
Temsirolimus—Dermatitis—Cyclosporine—psoriasis	6.04e-05	0.000241	CcSEcCtD
Temsirolimus—Pruritus—Hydrocortisone—psoriasis	6.03e-05	0.00024	CcSEcCtD
Temsirolimus—Headache—Cyclosporine—psoriasis	6e-05	0.000239	CcSEcCtD
Temsirolimus—Anaemia—Methotrexate—psoriasis	6e-05	0.000239	CcSEcCtD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—psoriasis	5.97e-05	0.00101	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Dexamethasone—psoriasis	5.95e-05	0.000237	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Betamethasone—psoriasis	5.95e-05	0.000237	CcSEcCtD
Temsirolimus—Vomiting—Mycophenolate mofetil—psoriasis	5.94e-05	0.000237	CcSEcCtD
Temsirolimus—Hypersensitivity—Triamcinolone—psoriasis	5.91e-05	0.000235	CcSEcCtD
Temsirolimus—Rash—Mycophenolate mofetil—psoriasis	5.89e-05	0.000235	CcSEcCtD
Temsirolimus—Dermatitis—Mycophenolate mofetil—psoriasis	5.89e-05	0.000235	CcSEcCtD
Temsirolimus—MTOR—B Cell Activation—NFKB1—psoriasis	5.89e-05	0.000997	CbGpPWpGaD
Temsirolimus—Headache—Mycophenolate mofetil—psoriasis	5.86e-05	0.000233	CcSEcCtD
Temsirolimus—ABCB1—Allograft Rejection—CXCL8—psoriasis	5.83e-05	0.000988	CbGpPWpGaD
Temsirolimus—Diarrhoea—Hydrocortisone—psoriasis	5.83e-05	0.000232	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—psoriasis	5.81e-05	0.000232	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Prednisone—psoriasis	5.77e-05	0.00023	CcSEcCtD
Temsirolimus—Dizziness—Prednisolone—psoriasis	5.77e-05	0.00023	CcSEcCtD
Temsirolimus—Asthenia—Triamcinolone—psoriasis	5.75e-05	0.000229	CcSEcCtD
Temsirolimus—Abdominal pain—Dexamethasone—psoriasis	5.75e-05	0.000229	CcSEcCtD
Temsirolimus—Body temperature increased—Betamethasone—psoriasis	5.75e-05	0.000229	CcSEcCtD
Temsirolimus—Body temperature increased—Dexamethasone—psoriasis	5.75e-05	0.000229	CcSEcCtD
Temsirolimus—Abdominal pain—Betamethasone—psoriasis	5.75e-05	0.000229	CcSEcCtD
Temsirolimus—Insomnia—Prednisone—psoriasis	5.73e-05	0.000228	CcSEcCtD
Temsirolimus—MTOR—Signaling by FGFR in disease—STAT3—psoriasis	5.72e-05	0.000968	CbGpPWpGaD
Temsirolimus—Nausea—Cyclosporine—psoriasis	5.69e-05	0.000227	CcSEcCtD
Temsirolimus—Pruritus—Triamcinolone—psoriasis	5.67e-05	0.000226	CcSEcCtD
Temsirolimus—Cough—Methotrexate—psoriasis	5.66e-05	0.000226	CcSEcCtD
Temsirolimus—MTOR—Signaling by VEGF—IL6—psoriasis	5.64e-05	0.000955	CbGpPWpGaD
Temsirolimus—Dizziness—Hydrocortisone—psoriasis	5.63e-05	0.000224	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—SOCS1—psoriasis	5.63e-05	0.000954	CbGpPWpGaD
Temsirolimus—Convulsion—Methotrexate—psoriasis	5.62e-05	0.000224	CcSEcCtD
Temsirolimus—MTOR—Signaling by Insulin receptor—IL6—psoriasis	5.6e-05	0.000948	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—STAT3—psoriasis	5.59e-05	0.000947	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—TYK2—psoriasis	5.56e-05	0.000942	CbGpPWpGaD
Temsirolimus—Nausea—Mycophenolate mofetil—psoriasis	5.55e-05	0.000221	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—psoriasis	5.52e-05	0.00022	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—psoriasis	5.52e-05	0.00022	CcSEcCtD
Temsirolimus—Arthralgia—Methotrexate—psoriasis	5.52e-05	0.00022	CcSEcCtD
Temsirolimus—Decreased appetite—Prednisone—psoriasis	5.51e-05	0.00022	CcSEcCtD
Temsirolimus—Rash—Prednisolone—psoriasis	5.5e-05	0.000219	CcSEcCtD
Temsirolimus—MTOR—Immune System—ITGAL—psoriasis	5.5e-05	0.000931	CbGpPWpGaD
Temsirolimus—Dermatitis—Prednisolone—psoriasis	5.49e-05	0.000219	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	5.49e-05	0.000219	CcSEcCtD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.47e-05	0.000927	CbGpPWpGaD
Temsirolimus—Fatigue—Prednisone—psoriasis	5.46e-05	0.000218	CcSEcCtD
Temsirolimus—Headache—Prednisolone—psoriasis	5.46e-05	0.000218	CcSEcCtD
Temsirolimus—Constipation—Prednisone—psoriasis	5.42e-05	0.000216	CcSEcCtD
Temsirolimus—Vomiting—Hydrocortisone—psoriasis	5.41e-05	0.000216	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—SOCS1—psoriasis	5.41e-05	0.000916	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NDUFA5—psoriasis	5.38e-05	0.000911	CbGpPWpGaD
Temsirolimus—Rash—Hydrocortisone—psoriasis	5.37e-05	0.000214	CcSEcCtD
Temsirolimus—Dermatitis—Hydrocortisone—psoriasis	5.36e-05	0.000214	CcSEcCtD
Temsirolimus—Headache—Hydrocortisone—psoriasis	5.34e-05	0.000213	CcSEcCtD
Temsirolimus—Dizziness—Triamcinolone—psoriasis	5.3e-05	0.000211	CcSEcCtD
Temsirolimus—Anaphylactic shock—Methotrexate—psoriasis	5.3e-05	0.000211	CcSEcCtD
Temsirolimus—Infection—Methotrexate—psoriasis	5.26e-05	0.00021	CcSEcCtD
Temsirolimus—Asthenia—Dexamethasone—psoriasis	5.22e-05	0.000208	CcSEcCtD
Temsirolimus—Asthenia—Betamethasone—psoriasis	5.22e-05	0.000208	CcSEcCtD
Temsirolimus—Nervous system disorder—Methotrexate—psoriasis	5.19e-05	0.000207	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—psoriasis	5.18e-05	0.000207	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Prednisone—psoriasis	5.18e-05	0.000207	CcSEcCtD
Temsirolimus—Nausea—Prednisolone—psoriasis	5.18e-05	0.000206	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—CXCL8—psoriasis	5.16e-05	0.000874	CbGpPWpGaD
Temsirolimus—Pruritus—Betamethasone—psoriasis	5.15e-05	0.000205	CcSEcCtD
Temsirolimus—Pruritus—Dexamethasone—psoriasis	5.15e-05	0.000205	CcSEcCtD
Temsirolimus—Skin disorder—Methotrexate—psoriasis	5.14e-05	0.000205	CcSEcCtD
Temsirolimus—MTOR—Immune System—REL—psoriasis	5.14e-05	0.000871	CbGpPWpGaD
Temsirolimus—Vomiting—Triamcinolone—psoriasis	5.1e-05	0.000203	CcSEcCtD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	5.06e-05	0.000857	CbGpPWpGaD
Temsirolimus—Nausea—Hydrocortisone—psoriasis	5.06e-05	0.000202	CcSEcCtD
Temsirolimus—Rash—Triamcinolone—psoriasis	5.06e-05	0.000202	CcSEcCtD
Temsirolimus—Dermatitis—Triamcinolone—psoriasis	5.05e-05	0.000201	CcSEcCtD
Temsirolimus—Anorexia—Methotrexate—psoriasis	5.05e-05	0.000201	CcSEcCtD
Temsirolimus—Headache—Triamcinolone—psoriasis	5.02e-05	0.0002	CcSEcCtD
Temsirolimus—Body temperature increased—Prednisone—psoriasis	5.01e-05	0.0002	CcSEcCtD
Temsirolimus—Abdominal pain—Prednisone—psoriasis	5.01e-05	0.0002	CcSEcCtD
Temsirolimus—MTOR—Immune System—IFIH1—psoriasis	4.99e-05	0.000845	CbGpPWpGaD
Temsirolimus—Diarrhoea—Dexamethasone—psoriasis	4.98e-05	0.000198	CcSEcCtD
Temsirolimus—Diarrhoea—Betamethasone—psoriasis	4.98e-05	0.000198	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—psoriasis	4.95e-05	0.000839	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—psoriasis	4.82e-05	0.000192	CcSEcCtD
Temsirolimus—Dizziness—Betamethasone—psoriasis	4.81e-05	0.000192	CcSEcCtD
Temsirolimus—Dizziness—Dexamethasone—psoriasis	4.81e-05	0.000192	CcSEcCtD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	4.8e-05	0.000814	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—HLA-B—psoriasis	4.8e-05	0.000814	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—JUN—psoriasis	4.8e-05	0.000813	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD8A—psoriasis	4.8e-05	0.000812	CbGpPWpGaD
Temsirolimus—Insomnia—Methotrexate—psoriasis	4.79e-05	0.000191	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—IL6—psoriasis	4.79e-05	0.000811	CbGpPWpGaD
Temsirolimus—Nausea—Triamcinolone—psoriasis	4.76e-05	0.00019	CcSEcCtD
Temsirolimus—ABCB1—Allograft Rejection—VEGFA—psoriasis	4.74e-05	0.000802	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HLA-C—psoriasis	4.73e-05	0.000801	CbGpPWpGaD
Temsirolimus—Dyspnoea—Methotrexate—psoriasis	4.72e-05	0.000188	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—psoriasis	4.71e-05	0.000188	CcSEcCtD
Temsirolimus—MTOR—Immune System—TNFAIP3—psoriasis	4.67e-05	0.000792	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Prednisone—psoriasis	4.67e-05	0.000186	CcSEcCtD
Temsirolimus—Vomiting—Betamethasone—psoriasis	4.63e-05	0.000184	CcSEcCtD
Temsirolimus—Vomiting—Dexamethasone—psoriasis	4.63e-05	0.000184	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—NFKB1—psoriasis	4.62e-05	0.000782	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HLA-B—psoriasis	4.61e-05	0.000781	CbGpPWpGaD
Temsirolimus—Decreased appetite—Methotrexate—psoriasis	4.6e-05	0.000183	CcSEcCtD
Temsirolimus—Rash—Dexamethasone—psoriasis	4.59e-05	0.000183	CcSEcCtD
Temsirolimus—Rash—Betamethasone—psoriasis	4.59e-05	0.000183	CcSEcCtD
Temsirolimus—Dermatitis—Betamethasone—psoriasis	4.58e-05	0.000183	CcSEcCtD
Temsirolimus—Dermatitis—Dexamethasone—psoriasis	4.58e-05	0.000183	CcSEcCtD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—IL6—psoriasis	4.58e-05	0.000776	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CYP2S1—psoriasis	4.57e-05	0.000775	CbGpPWpGaD
Temsirolimus—Gastrointestinal disorder—Methotrexate—psoriasis	4.57e-05	0.000182	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—psoriasis	4.57e-05	0.000182	CcSEcCtD
Temsirolimus—Headache—Dexamethasone—psoriasis	4.56e-05	0.000182	CcSEcCtD
Temsirolimus—Headache—Betamethasone—psoriasis	4.56e-05	0.000182	CcSEcCtD
Temsirolimus—Asthenia—Prednisone—psoriasis	4.55e-05	0.000181	CcSEcCtD
Temsirolimus—Pain—Methotrexate—psoriasis	4.53e-05	0.000181	CcSEcCtD
Temsirolimus—MTOR—Signaling by ERBB4—IL6—psoriasis	4.51e-05	0.000764	CbGpPWpGaD
Temsirolimus—Pruritus—Prednisone—psoriasis	4.48e-05	0.000179	CcSEcCtD
Temsirolimus—Diarrhoea—Prednisone—psoriasis	4.34e-05	0.000173	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—NFKB1—psoriasis	4.33e-05	0.000734	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Methotrexate—psoriasis	4.33e-05	0.000173	CcSEcCtD
Temsirolimus—Nausea—Betamethasone—psoriasis	4.32e-05	0.000172	CcSEcCtD
Temsirolimus—Nausea—Dexamethasone—psoriasis	4.32e-05	0.000172	CcSEcCtD
Temsirolimus—MTOR—Downstream signal transduction—IL6—psoriasis	4.31e-05	0.000729	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—IL6—psoriasis	4.29e-05	0.000726	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HLA-A—psoriasis	4.27e-05	0.000724	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—IL6—psoriasis	4.26e-05	0.000722	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HLA-A—psoriasis	4.26e-05	0.000721	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CRP—psoriasis	4.25e-05	0.000719	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—IL6—psoriasis	4.24e-05	0.000719	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—VEGFA—psoriasis	4.19e-05	0.00071	CbGpPWpGaD
Temsirolimus—Dizziness—Prednisone—psoriasis	4.19e-05	0.000167	CcSEcCtD
Temsirolimus—Abdominal pain—Methotrexate—psoriasis	4.19e-05	0.000167	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—psoriasis	4.19e-05	0.000167	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—STAT3—psoriasis	4.15e-05	0.000703	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—TNF—psoriasis	4.06e-05	0.000688	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NDUFA5—psoriasis	4.06e-05	0.000688	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.04e-05	0.000684	CbGpPWpGaD
Temsirolimus—Vomiting—Prednisone—psoriasis	4.03e-05	0.000161	CcSEcCtD
Temsirolimus—Rash—Prednisone—psoriasis	4e-05	0.000159	CcSEcCtD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	3.99e-05	0.000676	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—IL6—psoriasis	3.99e-05	0.000676	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—IL6—psoriasis	3.99e-05	0.000676	CbGpPWpGaD
Temsirolimus—Dermatitis—Prednisone—psoriasis	3.99e-05	0.000159	CcSEcCtD
Temsirolimus—FKBP1A—Disease—APOE—psoriasis	3.97e-05	0.000673	CbGpPWpGaD
Temsirolimus—Headache—Prednisone—psoriasis	3.97e-05	0.000158	CcSEcCtD
Temsirolimus—MTOR—Signaling by EGFR—IL6—psoriasis	3.96e-05	0.00067	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HLA-E—psoriasis	3.93e-05	0.000665	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—IL6—psoriasis	3.92e-05	0.000664	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HLA-DRB1—psoriasis	3.9e-05	0.000661	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—IL6—psoriasis	3.9e-05	0.000661	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Methotrexate—psoriasis	3.9e-05	0.000156	CcSEcCtD
Temsirolimus—MTOR—Signaling by NGF—STAT3—psoriasis	3.89e-05	0.000659	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NFKBIA—psoriasis	3.87e-05	0.000656	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCL20—psoriasis	3.85e-05	0.000652	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NDUFA5—psoriasis	3.83e-05	0.000648	CbGpPWpGaD
Temsirolimus—Asthenia—Methotrexate—psoriasis	3.8e-05	0.000151	CcSEcCtD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	3.77e-05	0.000639	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—SOCS1—psoriasis	3.77e-05	0.000639	CbGpPWpGaD
Temsirolimus—Nausea—Prednisone—psoriasis	3.76e-05	0.00015	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—ICAM1—psoriasis	3.75e-05	0.000635	CbGpPWpGaD
Temsirolimus—Pruritus—Methotrexate—psoriasis	3.75e-05	0.000149	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—NFKBIA—psoriasis	3.72e-05	0.00063	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NOS2—psoriasis	3.7e-05	0.000627	CbGpPWpGaD
Temsirolimus—Diarrhoea—Methotrexate—psoriasis	3.62e-05	0.000144	CcSEcCtD
Temsirolimus—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.6e-05	0.00061	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	3.54e-05	0.000599	CbGpPWpGaD
Temsirolimus—Dizziness—Methotrexate—psoriasis	3.5e-05	0.00014	CcSEcCtD
Temsirolimus—ABCB1—Metabolism—CYP2S1—psoriasis	3.45e-05	0.000585	CbGpPWpGaD
Temsirolimus—Vomiting—Methotrexate—psoriasis	3.37e-05	0.000134	CcSEcCtD
Temsirolimus—Rash—Methotrexate—psoriasis	3.34e-05	0.000133	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—psoriasis	3.34e-05	0.000133	CcSEcCtD
Temsirolimus—Headache—Methotrexate—psoriasis	3.32e-05	0.000132	CcSEcCtD
Temsirolimus—MTOR—Immune System—SOCS1—psoriasis	3.28e-05	0.000555	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CYP2S1—psoriasis	3.25e-05	0.000551	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—TYK2—psoriasis	3.17e-05	0.000537	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—psoriasis	3.17e-05	0.000536	CbGpPWpGaD
Temsirolimus—Nausea—Methotrexate—psoriasis	3.15e-05	0.000125	CcSEcCtD
Temsirolimus—CYP3A7—Metabolism—CARM1—psoriasis	3.09e-05	0.000523	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TYK2—psoriasis	3.03e-05	0.000514	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD8A—psoriasis	2.91e-05	0.000493	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—IL6—psoriasis	2.9e-05	0.000491	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CD4—psoriasis	2.87e-05	0.000486	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HLA-B—psoriasis	2.8e-05	0.000474	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—APOE—psoriasis	2.78e-05	0.000471	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—LEP—psoriasis	2.78e-05	0.000471	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD4—psoriasis	2.75e-05	0.000466	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CD4—psoriasis	2.74e-05	0.000464	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—IL6—psoriasis	2.72e-05	0.000461	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.68e-05	0.000453	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NFKBIA—psoriasis	2.59e-05	0.000439	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HLA-A—psoriasis	2.59e-05	0.000439	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.58e-05	0.000436	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—JUN—psoriasis	2.57e-05	0.000435	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NDUFA5—psoriasis	2.5e-05	0.000424	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CRP—psoriasis	2.47e-05	0.000419	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—NFKB1—psoriasis	2.47e-05	0.000419	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HLA-A—psoriasis	2.39e-05	0.000405	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—NFKB1—psoriasis	2.37e-05	0.000402	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HLA-DRB1—psoriasis	2.37e-05	0.000401	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.34e-05	0.000396	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ICAM1—psoriasis	2.27e-05	0.000385	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NFKBIA—psoriasis	2.26e-05	0.000382	CbGpPWpGaD
Temsirolimus—MTOR—Disease—APOE—psoriasis	2.23e-05	0.000378	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CARM1—psoriasis	2.23e-05	0.000378	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CYP2S1—psoriasis	2.13e-05	0.00036	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TYK2—psoriasis	2.12e-05	0.00036	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—STAT3—psoriasis	2.12e-05	0.00036	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—SOCS1—psoriasis	2.12e-05	0.000359	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NOS2—psoriasis	2.08e-05	0.000353	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2e-05	0.000339	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CAT—psoriasis	1.9e-05	0.000322	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CXCL8—psoriasis	1.85e-05	0.000313	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—TYK2—psoriasis	1.85e-05	0.000313	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.77e-05	0.000299	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IFNG—psoriasis	1.73e-05	0.000293	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—JUN—psoriasis	1.72e-05	0.000291	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TYK2—psoriasis	1.71e-05	0.000289	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CARM1—psoriasis	1.69e-05	0.000285	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD4—psoriasis	1.67e-05	0.000283	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NFKB1—psoriasis	1.65e-05	0.00028	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CARM1—psoriasis	1.59e-05	0.000269	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—APOE—psoriasis	1.56e-05	0.000265	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—LEP—psoriasis	1.56e-05	0.000265	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—IL6—psoriasis	1.55e-05	0.000263	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CD4—psoriasis	1.54e-05	0.000261	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—VEGFA—psoriasis	1.5e-05	0.000254	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—JUN—psoriasis	1.5e-05	0.000253	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—STAT3—psoriasis	1.49e-05	0.000252	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—IL6—psoriasis	1.48e-05	0.000251	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—APOE—psoriasis	1.48e-05	0.00025	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NFKBIA—psoriasis	1.46e-05	0.000247	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—NFKB1—psoriasis	1.44e-05	0.000244	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CAT—psoriasis	1.37e-05	0.000233	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—STAT3—psoriasis	1.29e-05	0.000219	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—PPARG—psoriasis	1.29e-05	0.000218	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TYK2—psoriasis	1.19e-05	0.000202	CbGpPWpGaD
Temsirolimus—MTOR—Disease—STAT3—psoriasis	1.19e-05	0.000202	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—psoriasis	1.13e-05	0.000192	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—APOE—psoriasis	1.07e-05	0.000181	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CXCL8—psoriasis	1.04e-05	0.000176	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—IL6—psoriasis	1.04e-05	0.000176	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CARM1—psoriasis	1.04e-05	0.000176	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CAT—psoriasis	1.04e-05	0.000176	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CAT—psoriasis	9.77e-06	0.000165	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—JUN—psoriasis	9.67e-06	0.000164	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NFKB1—psoriasis	9.31e-06	0.000158	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—PPARG—psoriasis	9.3e-06	0.000157	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL6—psoriasis	9.03e-06	0.000153	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—VEGFA—psoriasis	8.45e-06	0.000143	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STAT3—psoriasis	8.36e-06	0.000142	CbGpPWpGaD
Temsirolimus—MTOR—Disease—IL6—psoriasis	8.34e-06	0.000141	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—APOE—psoriasis	8.06e-06	0.000136	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—APOE—psoriasis	7.59e-06	0.000129	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—PPARG—psoriasis	7.02e-06	0.000119	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—PPARG—psoriasis	6.61e-06	0.000112	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CAT—psoriasis	6.39e-06	0.000108	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—psoriasis	6.38e-06	0.000108	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—IL6—psoriasis	5.84e-06	9.89e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—APOE—psoriasis	4.96e-06	8.41e-05	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—PPARG—psoriasis	4.32e-06	7.32e-05	CbGpPWpGaD
